Oncodesign Precision Medicine

Oncodesign Precision Medicine Société anonyme is a biopharmaceutical company focused on precision medicine. Its pipeline includes OPM-101, a RIPK2 inhibitor for inflammatory bowel disease and immuno-oncology; OPM-102 for cancer; and OPM-201, a LRRK2 inhibitor for Parkinson's disease. The company also develops a radiotheranostic molecule portfolio for the diagnosis and treatment of advanced digestive cancers, as well as treatments for pancreatic and other cancers. Founded in 1995, it is based in Dijon, France.